EMBEDA
Drug
PFIZER INC.
Total Payments
$3.9M
Transactions
6,979
Doctors
3,400
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $14.74 | 1 | 1 |
| 2021 | $1,214 | 2 | 0 |
| 2020 | $38,287 | 23 | 0 |
| 2019 | $856,625 | 811 | 511 |
| 2018 | $1.0M | 455 | 145 |
| 2017 | $1.9M | 5,687 | 3,003 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.4M | 429 | 86.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $304,250 | 198 | 7.9% |
| Food and Beverage | $118,376 | 6,214 | 3.1% |
| Consulting Fee | $70,525 | 23 | 1.8% |
| Travel and Lodging | $16,373 | 115 | 0.4% |
Payments by Type
Research
$3.4M
429 transactions
General
$509,525
6,550 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DENVER HEALTH RADARS SUBSCRIPTION AND RADARS SYSTEM SERVICE ORDER | Pfizer Inc. | $1.1M | 0 |
| AN OPENLABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PF06412528 IN CHILDREN 717 YEARS FOR THE TREATMENT OF MODERATETOSEVERE PAIN | PFIZER INC. | $941,620 | 0 |
| THE RESEARCHED ABUSE DIVERSION AND ADDICTIONRELATED SURVEILLANCE RADARS SYSTEM SHALL PROVIDE PFIZER WITH ONGOING SURVEILLANCE TO CONTINUALLY MONITOR THE ABUSE MISUSE AND DIVERSION OF EMBEDA AND TROXYCA AND OTHER RELEVANT PRESCRIPTION OPIOIDS | PFIZER INC. | $809,000 | 0 |
| PROVIDER SHALL PROVIDE PFIZER WITH ONGOING SURVEILLANCE TO CONTINUALLY MONITOR THE ABUSE MISUE AND DIVERSION OF EMBEDA AND TROXYCA AND OTHER RELEVANT PRESCRIPTION OPIOIDS AS COMPARATORS | PFIZER INC. | $320,000 | 0 |
| RADARS SYSTEM SERVICE ORDER | PFIZER INC. | $160,000 | 0 |
| THE OPIODSPARING EFFECT OF DICLOFENAC EPOLAMINE PATCH FOR TOTAL KNEE REPLACEMENTS | PFIZER INC. | $17,891 | 0 |
| A PHASE 1 OPENLABEL RANDOMIZED TWOWAY SINGLEDOSE CROSSOVER STUDY IN HEALTHY VOLUNTEERS TO ASSESS THE BIOEQUIVALENCE OF MORPHINE FOLLOWING ADMINISTRATION UNDER FASTING CONDITIONS OF PF06412528 EMBEDAREGISTERED 60 MG24 MG CAPSULES MANUFACTURED AT COATING PLACE COMPARED WITH CAPSULES MANUFACTURED AT ACTAVIS | PFIZER INC. | $15,975 | 0 |
Top Doctors Receiving Payments for EMBEDA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Anesthesiology | Dallas, TX | $2,800 | 1 |
| , MD | Physical Medicine & Rehabilitation | Overland Park, KS | $2,769 | 4 |
| , MD | Student in an Organized Health Care Education/Training Program | Bastrop, TX | $2,737 | 7 |
| , MD | Anesthesiology | Brooklyn, NY | $2,718 | 4 |
| , MD,PMR | Physical Medicine & Rehabilitation | White Plains, NY | $2,688 | 6 |
| , M.D | Physical Medicine & Rehabilitation | Fairfield, CT | $2,675 | 7 |
| , MD | Physical Medicine & Rehabilitation | Alexandria, VA | $2,650 | 10 |
| , D.O | Anesthesiology | Round Rock, TX | $2,630 | 4 |
| , MD | Physical Medicine & Rehabilitation | Waldorf, MD | $2,613 | 4 |
| , D.O | Physical Medicine & Rehabilitation | La Jolla, CA | $2,608 | 6 |
| , M.D | Interventional Pain Medicine | Owings Mills, MD | $2,606 | 2 |
| , DO | Diagnostic Radiology | Paducah, KY | $2,604 | 9 |
| , MD | Rheumatology | Glenview, IL | $2,593 | 3 |
| , MD | Pain Medicine | Chattanooga, TN | $2,583 | 6 |
| , MD | Pain Medicine | Edmond, OK | $2,544 | 7 |
| , MD | Obesity Medicine | Tarzana, CA | $2,520 | 2 |
| Kenneth Sun | — | Wind Gap, PA | $2,500 | 1 |
| , MD | Anesthesiology | Aurora, CO | $2,250 | 1 |
| , M.D | Physical Medicine & Rehabilitation | Lambertville, MI | $2,213 | 4 |
| , MD | Anesthesiology | Raleigh, NC | $2,170 | 2 |
| , M.D | Anesthesiology | Dubuque, IA | $2,158 | 3 |
| , MD | Interventional Pain Medicine | Toledo, OH | $1,914 | 3 |
| , M.D | Physical Medicine & Rehabilitation | Topeka, KS | $1,905 | 7 |
| , MD | Medical Toxicology | Denver, CO | $1,900 | 1 |
| , M.D | Interventional Pain Medicine | Indianapolis, IN | $1,879 | 3 |
Ad
Manufacturing Companies
- PFIZER INC. $2.8M
- Pfizer Inc. $1.1M
- PFIZER PHARMACEUTICALS LLC $308.31
Product Information
- Type Drug
- Total Payments $3.9M
- Total Doctors 3,400
- Transactions 6,979
About EMBEDA
EMBEDA is a drug associated with $3.9M in payments to 3,400 healthcare providers, recorded across 6,979 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2022. In 2022, $14.74 was paid across 1 transactions to 1 doctors.
The most common payment nature for EMBEDA is "Unspecified" ($3.4M, 86.8% of total).
EMBEDA is associated with 7 research studies, including "DENVER HEALTH RADARS SUBSCRIPTION AND RADARS SYSTEM SERVICE ORDER" ($1.1M).